Get notified when ZURA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- 31% Opposition To Equity Plan Amendment (new) — Elevated opposition suggests shareholder concerns about dilution or compensation practices that warrant board attention.
- Two Directors Received ~29% Opposition Votes (new) — Jarrett and Munshi faced materially higher opposition than other directors, signaling potential shareholder concerns about their board service.
Zura Bio shareholders approve amended equity plan despite 31% opposition
Filed June 18, 2026 · Period ending June 17, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved the amended 2023 Equity Incentive Plan with 69.0% support (38.9M for vs 17.4M against), reflecting elevated 31% opposition that suggests meaningful shareholder concern about dilution or compensation practices.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
medium
Directors Jennifer Jarrett and Amit Munshi were re-elected but received only 70.7% and 71.5% support respectively, with over 16 million votes against each, indicating notable shareholder opposition compared to the six other directors who received over 99% support.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Shareholders ratified WithumSmith+Brown, PC as independent auditor for fiscal 2026 with 99.7% support (74.3M for vs 30,527 against), a routine approval level.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CHAR 10-Q) is open in full — no account needed.
Partner
Trade ZURA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 21, 2026 7:27 AM